QIAGEN N.V. (QGEN)
Qiagen (QGEN) Soars 16.6%: Is Further Upside Left in the Stock?
Qiagen (QGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Qiagen N.V. (QGEN) Presents at 44th Annual J.P.
Qiagen N.V. (QGEN) Presents at 44th Annual J.P.
Qiagen (QGEN) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Qiagen (QGEN) Up 6.3% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
Qiagen N.V. (QGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Qiagen N.V. (QGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Qiagen N.V. (QGEN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Qiagen N.V. (QGEN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Qiagen N.V. (QGEN) Deep Dive Into Sample Technologies: Leadership, Innovation and Future Expansion Transcript
Qiagen N.V. ( QGEN ) Deep Dive Into Sample Technologies: Leadership, Innovation and Future Expansion November 21, 2025 9:00 AM EST Company Participants Domenica Martorana - Associate Director of Global Investor Relations Thierry Bernard - CEO, MD & Member of Management Board Daniel Wendorff John Gilardi - VP & Head of Corporate Communications Michael Scheffler Nitin Sood - Senior VP & Head of Product Portfolio & Innovation Fernando Beils Justus Krause-Harder Presentation Domenica Martorana Associate Director of Global Investor Relations Welcome to our next QIAGEN Deep Dive.
Qiagen N.V. (QGEN) Presents at Jefferies London Healthcare Conference 2025 Transcript
Qiagen N.V. ( QGEN ) Jefferies London Healthcare Conference 2025 November 19, 2025 5:30 AM EST Company Participants Roland Sackers - CFO, MD & Member of Management Board Daniel Wendorff John Gilardi - VP & Head of Corporate Communications Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Welcome, everybody.
CellBxHealth rises on Qiagen tie-up to push Parsortix into more drug-development projects
Shares in CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY, OTCQB:ANPCF) climbed 7% to 1.93p after the company unveiled a collaboration with Qiagen designed to bring its Parsortix circulating tumour cell platform to a wider range of pharmaceutical partners. The agreement gives Qiagen the ability to bundle Parsortix into projects alongside its own molecular technologies, including polymerase chain reaction, digital polymerase chain reaction and next-generation sequencing.
CellBxHealth strikes co-marketing deal with Qiagen to widen use of Parsortix cancer platform
CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY, OTCQB:ANPCF) has agreed a collaboration and co-marketing deal with Qiagen that will allow the diagnostics group to promote the UK company's Parsortix system to drugmakers, opening the door to new projects in circulating tumour cell research and early diagnostic development. The non-exclusive agreement enables Qiagen to offer the Parsortix platform to its pharmaceutical partners as part of projects that combine circulating tumour cell enrichment with Qiagen's polymerase chain reaction, digital polymerase chain reaction and next-generation sequencing technologies.
Qiagen N.V. (QGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Qiagen N.V. ( QGEN ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 12:40 PM EST Company Participants Thierry Bernard - CEO, MD & Member of Management Board Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC All right.
Qiagen (QGEN) International Revenue in Focus: Trends and Expectations
Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
